<DOC>
	<DOCNO>NCT02709421</DOCNO>
	<brief_summary>Post-endoscopic retrograde cholangiopancreatography ( ERCP ) pancreatitis ( PEP ) remain frequent adverse event ERCP . Rectal indomethacin , one kind classic NSAIDs , prove effective reduce incidence PEP . It widely use prevent PEP patient , especially potentially high risk PEP . However , rectal indomethacin completely eradicate occurrence PEP . The rate PEP patient receive indomethacin range 3.2 % 9.2 % . The risk factor PEP patient receive rectal indomethacin remain unclear . The aim study identify potential risk factor high-risk patient whose received administration prophylactic rectal indomethacin ERCP .</brief_summary>
	<brief_title>Risk Factors Post-ERCP Pancreatitis Patients Receiving Rectal Indomethacin</brief_title>
	<detailed_description />
	<mesh_term>Pancreatitis</mesh_term>
	<mesh_term>Indomethacin</mesh_term>
	<criteria>Undergoing diagnostic interventional ERCP Receiving administration rectal indomethacin ( 100mg ) ERCP High risk patient determine discretion endoscopists Dose 100mg Acute pancreatitis within 3 day ERCP Average risk patient discretion endoscopists Using NSAIDs within 7 day ERCP Without cannulation attempt Administration rectal indomethacin ERCP</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>post-Endoscopic Retrograde cholangiopancreatography pancreatitis</keyword>
	<keyword>Risk factor</keyword>
	<keyword>Indomethacin</keyword>
</DOC>